Literature DB >> 30740455

Empagliflozin as an adjunctive therapy for type 1 diabetes.

Richard J MacIsaac1,2, Melissa H Lee1,2, Sybil A McAuley1,2, Glenn M Ward1,2, David N O'Neal1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30740455      PMCID： PMC6330613          DOI： 10.21037/atm.2018.12.52

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Temporal patterns in overweight and obesity in Type 1 diabetes.

Authors:  B Conway; R G Miller; T Costacou; L Fried; S Kelsey; R W Evans; T J Orchard
Journal:  Diabet Med       Date:  2010-04       Impact factor: 4.359

2.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

3.  Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.

Authors:  Robert R Henry; Payal Thakkar; Cindy Tong; David Polidori; Maria Alba
Journal:  Diabetes Care       Date:  2015-10-20       Impact factor: 19.112

4.  Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Authors:  Paresh Dandona; Chantal Mathieu; Moshe Phillip; Lars Hansen; Steven C Griffen; Diethelm Tschöpe; Fredrik Thorén; John Xu; Anna Maria Langkilde
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-14       Impact factor: 32.069

Review 5.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

6.  Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

Authors:  Ele Ferrannini; Simona Baldi; Silvia Frascerra; Brenno Astiarraga; Tim Heise; Roberto Bizzotto; Andrea Mari; Thomas R Pieber; Elza Muscelli
Journal:  Diabetes       Date:  2016-02-09       Impact factor: 9.461

Review 7.  Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.

Authors:  Christian Seerup Frandsen; Thomas Fremming Dejgaard; Sten Madsbad
Journal:  Lancet Diabetes Endocrinol       Date:  2016-03-09       Impact factor: 32.069

8.  Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.

Authors:  J A McKnight; S H Wild; M J E Lamb; M N Cooper; T W Jones; E A Davis; S Hofer; M Fritsch; E Schober; J Svensson; T Almdal; R Young; J T Warner; B Delemer; P F Souchon; R W Holl; W Karges; D M Kieninger; S Tigas; A Bargiota; C Sampanis; V Cherubini; R Gesuita; I Strele; S Pildava; K J Coppell; G Magee; J G Cooper; S F Dinneen; K Eeg-Olofsson; A-M Svensson; S Gudbjornsdottir; H Veeze; H-J Aanstoot; M Khalangot; W V Tamborlane; K M Miller
Journal:  Diabet Med       Date:  2015-02-21       Impact factor: 4.359

9.  Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.

Authors:  Satish K Garg; Robert R Henry; Phillip Banks; John B Buse; Melanie J Davies; Gregory R Fulcher; Paolo Pozzilli; Diane Gesty-Palmer; Pablo Lapuerta; Rafael Simó; Thomas Danne; Darren K McGuire; Jake A Kushner; Anne Peters; Paul Strumph
Journal:  N Engl J Med       Date:  2017-09-13       Impact factor: 91.245

10.  Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions.

Authors:  David M Nathan; Margaret Bayless; Patricia Cleary; Saul Genuth; Rose Gubitosi-Klug; John M Lachin; Gayle Lorenzi; Bernard Zinman
Journal:  Diabetes       Date:  2013-12       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.